Researchers Warn of Patient Safety Risks from Unregulated Online Health Tests

Web Reporter
4 Min Read

Easy access to health screening tests advertised online is raising concerns about patient safety, with researchers warning that many products make unsupported claims and could lead to unnecessary medical procedures, false reassurance or avoidable anxiety.

A study by researchers at the University of St Andrews in Scotland examined 50 health tests promoted by online retailers and private clinics across the United Kingdom. The products covered a wide range of services, including gut microbiome analysis, blood counts, genetic testing, liver and lung function assessments, cortisol measurements, breast and pelvic examinations, chest X-rays and ultrasounds.

Prices varied considerably, starting at £6.99 (€8.36) for an at-home kidney albumin rapid test and reaching £14,000 (€16,751) for a package marketed as a “platinum assessment”. The most expensive offer included multiple tests, medical imaging and a physical examination. Some providers also promoted luxury hotel or spa packages, while celebrities and social media influencers endorsed other services.

The analysis, published in the journal BMJ Open, found that many providers made claims that were not supported by scientific evidence or promoted screening procedures that are not recommended for people without symptoms by the UK’s National Health Service.

Sixteen of the tests claimed they could help people live longer, while 36 promised earlier diagnosis and improved health outcomes. However, only 15 explained possible disadvantages, including inaccurate results and risks associated with intimate physical examinations.

One retailer used disease-related death figures to promote its assessments, suggesting that some deaths could have been avoided if people had purchased its screening package.

The researchers also identified widespread promotion of intimate examinations. Fourteen providers offered testicular examinations, 13 offered breast examinations and nine advertised pelvic examinations for people without concerning symptoms. These procedures are not recommended as routine screening for everyone by the NHS.

Concerns over misleading claims

The researchers said consumer health tests were widely available despite limited regulatory safeguards. They acknowledged that home testing could help address gaps in healthcare services, but stressed that products should be supported by reliable evidence.

Poor-quality screening can produce false positives, which may trigger unnecessary investigations, and false negatives that give people a misleading sense of security. Consumers may also spend substantial amounts on tests that provide little or no medical benefit.

The findings come as regulators face growing scrutiny over health-related advertising. On Wednesday, the UK’s Advertising Standards Authority (ASA) upheld a ban on advertisements for an at-home testosterone blood test marketed by online healthcare provider Voy.

The watchdog ruled that the adverts were misleading because they linked common symptoms such as fatigue and irritability to low testosterone in a way that encouraged men to purchase testing kits. Voy argued that it had not suggested low testosterone was the only possible explanation, but the ASA ordered the company not to exaggerate the connection.

The St Andrews researchers said the limited number of cases reaching regulators pointed to a wider oversight problem, describing the issue as both a regulatory gap and a patient safety concern.

TAGGED:
Share This Article
Leave a comment

Leave a Reply